

TABLE 3
Prevalence estimates of use of cancer screening tests among American Indian/Alaska Native and non-Hispanic White adults resident in CHSDA counties—Behavioral Risk Factor Surveillance System, 2000–2006^a

	NHW Total ^a		AI/AN Total ^a		Northern Plains ^b		Alaska ^c		Southern Plains ^d		Pacific Coast ^e		East ^f		Southwest ^g	
	% ^h	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
Mammography within 2 years, women aged 40+ ⁱ	76.0	(75.5–76.5)	68.7	(64.7–72.4)	73.9	(67.8–79.3)	75.9	(69.6–81.2)	71.3	(66.2–76.0)	63.3	(52.3–73.1)	70.7	(59.7–79.7)	65.0	(58.4–71.0)
Papanicolaou (Pap) test within 3 years, women without hysterectomy ^j	83.7	(83.3–84.1)	79.3	(76.4–82.0)	83.3	(79.1–86.8)	87.5	(84.5–90.1)	77.7	(73.7–81.3)	76.4	(69.1–82.4)	74.9	(64.7–82.9)	80.1	(76.4–83.4)
Prostate specific antigen test within 1 year, men aged 50–75 ^j	53.0	(52.3–53.6)	44.4	(39.2–49.7)	50.0	(42.4–57.6)	34.8	(27.8–42.5)	45.4	(40.1–50.7)	45.4	(35.2–56.1)	43.4	(34.0–53.4)	41.6	(35.9–47.5)
Fecal occult blood test within 1 year or endoscopy within 5 years, aged 50+ ^j	54.3	(53.8–54.8)	40.2	(35.5–45.0)	36.0	(29.1–43.5)	49.4	(42.8–56.1)	42.4	(38.1–46.9)	41.1	(31.5–51.5)	41.3	(32.5–50.7)	33.8	(28.8–39.1)
Male	56.0	(55.2–56.8)	39.6	(32.7–47.0)	26.0	(18.4–35.4)	42.9	(33.6–52.6)	46.4	(39.5–53.5)	45.9	(32.3–60.2)	29.8	(19.9–42.1)	33.6	(26.1–42.0)
Female	53.1	(52.4–53.8)	41.4	(35.9–47.1)	45.2	(36.2–54.6)	55.1	(46.0–63.8)	38.8	(33.6–44.3)	40.0	(27.8–53.6)	53.5	(41.7–64.9)	33.9	(27.6–40.8)

CHSDA indicates Contract Health Service Delivery Areas of the Indian Health Service; NHW, non-Hispanic whites; AI/AN, American Indians/Alaska Natives; 95% CI, 95% confidence interval.

^aData from 33 US states (includes states listed in the footnotes below).

^bAI/AN in Indiana, Iowa, Michigan, Minnesota, Montana, Nebraska, North Dakota, South Dakota, Wisconsin, and Wyoming.

^cAI/AN in Alaska.

^dAI/AN in Kansas, Oklahoma, and Texas.

^eAI/AN in California, Idaho, Oregon, and Washington.

^fAI/AN in Alabama, Connecticut, Florida, Louisiana, Maine, Massachusetts, Mississippi, New York, North Carolina, Rhode Island, and South Carolina.

^gAI/AN in Arizona, Colorado, Nevada, New Mexico, and Utah.

^hAll prevalence estimates are weighted and age-adjusted to the 2000 US standard population. “Refused” and “don’t know” responses are excluded.

ⁱ2000, 2002, 2004, and 2006 (AI/AN estimates do not include Massachusetts).

^j2001, 2002, 2004, and 2006 (AI/AN estimates do not include Massachusetts).

